Senescence also plays a dual role in therapy resistance: genotoxic therapies such as carboplatin/paclitaxel induce senescence in melanoma cells, rendering them susceptible to Bcl2 inhibitors, while targeted BRAF/MEK inhibition produces senescent-like cells resistant to such treatments [311]. The gene discussed is BRAF; the disease is melanoma.